Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNG | P07510 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CHRND | Q07001 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16164843 | 0.76 | HDAC3 (0.46) | ANPEPNPC1 | |
| SCHEMBL15974646 | 0.74 | MDM2 (0.49) | CES2CES1MDM2S1PR3 | |
| SCHEMBL2763396 | 0.73 | EPHX2 (0.55) | RAB9ANPC1 | |
| SCHEMBL17391567 | 0.71 | S1PR3 (0.49) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL15973225 | 0.71 | S1PR3 (0.49) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL14830614 | 0.71 | S1PR3 (0.49) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL14595548 | 0.70 | NPC1 (0.63) | RAB9ANPC1S1PR3 | |
| SCHEMBL2763180 | 0.69 | NR4A1 (0.46) | PTPN1RAB9ANPC1 | |
| SCHEMBL15094383 | 0.68 | CES2 (0.68) | CES2CES1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL17843611 | 0.67 | CES2 (0.75) | CES2CES1CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825264-B2 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| EP-1899320-B1 | SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KV1 .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20080188520-A1 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2008-08-07 | — | — | US | disclosed |
| EP-1899320-A1 | SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136305-A1 | SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI-AVENTIS (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188520-A1 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | KCNH1, MLLT3, CYP1A2 | CES2 817/4885CES1 1037/4885MDM2 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.